Valproate pregnancy prevention scheme: what are the barriers to enrolling patients and how do we meet them?
Musa Mamman WatilaAlistair JamesKaren MilneGraham MackayPublished in: BMJ neurology open (2023)
A significant proportion of women continue valproate treatment without meeting the PPP requirement. This is linked to their indication for prescription and their comorbidities. Collaborative input from relevant specialities and primary care is required to fully achieve PPP if a national valproate database is to be established.